The UK government has this month signed the United Nations Convention on International Settlement Agreements Resulting from Mediation...

Ellen Lambrix and Adam Coughlin from Bristows' Commercial IP team attended the BioIntegrates conference in London on 16 May 2023. With...

In the recent case of Musst Holdings Ltd v Astra Asset Management UK Ltd [2023] EWCA Civ 128, the Court considered whether a novation was...

Cell and gene therapies (CGTs) are highly complex and sophisticated technologies with a lot of constituent parts. To bring a product to...

Platform technologies, often the core business of a biotech or techbio company, can be extremely valuable assets. Whether it’s a high...

On 26 January 2023, Science Minister George Freeman announced the formal establishment of the Advanced Research and Invention Agency...

Last month, Atara Biotherapeutics’ Ebvallo was granted marketing authorisation in the EU - the first off-the-shelf T-cell immunotherapy...

As reported by The Athletic (subscription required) Manchester United's front-of-shirt sponsor TeamViewer appears to be under pressure...

Which is more sensible, sacrificing hundreds of laboratory mice during the development of a therapeutic or using highly advanced model...

UCLB, the commercialisation company of UCL, held a Winter Showcase event on 16 November 2022 to highlight some of their recent successes...

On Tuesday evening, Bristows hosted an IPSoc panel discussion on AI and IP. We were lucky to have a dreamy panel consisting of: Jacob...

One of the most important decisions when embarking on the digital transformation process is deciding on the deal structure. There are a...